393 related articles for article (PubMed ID: 33895806)
1. Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies.
Rozenbaum MH; Garcia A; Grima D; Tran D; Bhambri R; Stewart M; Li B; Heeg B; Postma M; Masri A
Eur Heart J Qual Care Clin Outcomes; 2022 Aug; 8(5):529-538. PubMed ID: 33895806
[TBL] [Abstract][Full Text] [Related]
2. Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms.
Elliott P; Gundapaneni B; Sultan MB; Ines M; Garcia-Pavia P
Eur J Heart Fail; 2023 Nov; 25(11):2060-2064. PubMed ID: 37434378
[TBL] [Abstract][Full Text] [Related]
3. Estimating the Effect of Tafamidis on Cardiovascular-Related Hospitalization in NYHA Class III Patients with Transthyretin Amyloid Cardiomyopathy in the Presence of Death.
Li H; Rozenbaum M; Casey M; Sultan MB
Cardiology; 2022; 147(4):398-405. PubMed ID: 35853436
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
Elliott P; Drachman BM; Gottlieb SS; Hoffman JE; Hummel SL; Lenihan DJ; Ebede B; Gundapaneni B; Li B; Sultan MB; Shah SJ
Circ Heart Fail; 2022 Jan; 15(1):e008193. PubMed ID: 34923848
[TBL] [Abstract][Full Text] [Related]
5. Long-term survival in people with transthyretin amyloid cardiomyopathy who took tafamidis: A Plain Language Summary.
Elliott P; Drachman BM; Gottlieb SS; Hoffman JE; Hummel SL; Lenihan DJ; Ebede B; Gundapaneni B; Li B; Sultan MB; Shah SJ
Future Cardiol; 2023 Jan; 19(1):7-17. PubMed ID: 36715498
[TBL] [Abstract][Full Text] [Related]
6. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.
Damy T; Garcia-Pavia P; Hanna M; Judge DP; Merlini G; Gundapaneni B; Patterson TA; Riley S; Schwartz JH; Sultan MB; Witteles R
Eur J Heart Fail; 2021 Feb; 23(2):277-285. PubMed ID: 33070419
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy.
Kazi DS; Bellows BK; Baron SJ; Shen C; Cohen DJ; Spertus JA; Yeh RW; Arnold SV; Sperry BW; Maurer MS; Shah SJ
Circulation; 2020 Apr; 141(15):1214-1224. PubMed ID: 32078382
[TBL] [Abstract][Full Text] [Related]
9. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.
Park J; Egolum U; Parker S; Andrews E; Ombengi D; Ling H
Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059
[No Abstract] [Full Text] [Related]
10. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
Maurer MS; Schwartz JH; Gundapaneni B; Elliott PM; Merlini G; Waddington-Cruz M; Kristen AV; Grogan M; Witteles R; Damy T; Drachman BM; Shah SJ; Hanna M; Judge DP; Barsdorf AI; Huber P; Patterson TA; Riley S; Schumacher J; Stewart M; Sultan MB; Rapezzi C;
N Engl J Med; 2018 Sep; 379(11):1007-1016. PubMed ID: 30145929
[TBL] [Abstract][Full Text] [Related]
11. Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study.
Garcia-Pavia P; Sultan MB; Gundapaneni B; Sekijima Y; Perfetto F; Hanna M; Witteles R
JACC Heart Fail; 2024 Jan; 12(1):150-160. PubMed ID: 37943223
[TBL] [Abstract][Full Text] [Related]
12. Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy.
Rozenbaum MH; Tran D; Bhambri R; Nativi-Nicolau J
Am J Cardiovasc Drugs; 2022 Jul; 22(4):445-450. PubMed ID: 35353352
[TBL] [Abstract][Full Text] [Related]
13. Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis.
Vong C; Boucher M; Riley S; Harnisch LO
Am J Cardiovasc Drugs; 2021 Sep; 21(5):535-543. PubMed ID: 33770392
[TBL] [Abstract][Full Text] [Related]
14. Association of Tafamidis With Health Status in Patients With ATTR Cardiac Amyloidosis: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial.
Sperry BW; Hanna M; Maurer MS; Nativi-Nicolau J; Floden L; Stewart M; Wyrwich KW; Barsdorf AI; Kapadia H; Spertus JA
JAMA Cardiol; 2023 Mar; 8(3):275-280. PubMed ID: 36723935
[TBL] [Abstract][Full Text] [Related]
15. Tafamidis and quality of life in people with transthyretin amyloid cardiomyopathy in the study ATTR-ACT: A plain language summary.
Hanna M; Damy T; Grogan M; Stewart M; Gundapaneni B; Sultan MB; Maurer MS
Future Cardiol; 2022 Mar; 18(3):165-172. PubMed ID: 34779246
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of systematic screening and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with heart failure with preserved ejection fraction (HFpEF) in United States.
Lau ATC; DiDomenico RJ; Kim K
Int J Cardiol; 2024 Mar; 398():131598. PubMed ID: 37979789
[TBL] [Abstract][Full Text] [Related]
17. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
Rapezzi C; Elliott P; Damy T; Nativi-Nicolau J; Berk JL; Velazquez EJ; Boman K; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574
[TBL] [Abstract][Full Text] [Related]
19. Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
Maurer MS; Elliott P; Merlini G; Shah SJ; Cruz MW; Flynn A; Gundapaneni B; Hahn C; Riley S; Schwartz J; Sultan MB; Rapezzi C;
Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611125
[TBL] [Abstract][Full Text] [Related]
20. Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy.
Grogan M; Davis MK; Crespo-Leiro MG; Sultan MB; Gundapaneni B; Stedile Angeli F; Hanna M
Eur J Heart Fail; 2024 Mar; 26(3):612-615. PubMed ID: 38439606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
